#CureSMA2021 – Spinraza Leads to Better Swallowing, Farther Walking

#CureSMA2021 – Spinraza Leads to Better Swallowing, Farther Walking

296823

#CureSMA2021 – Spinraza Leads to Better Swallowing, Farther Walking

Children with spinal muscular atrophy (SMA) who started taking Spinraza (nusinsersen) before symptoms appeared retained their ability to swallow after approximately four years, while youngsters with later-onset SMA walked farther with less fatigue. These results, from analyses performed on multiple ongoing clinical trials, were presented by Biogen, Spinraza’s developer, at the 2021 Virtual SMA Research & Clinical Care Meeting, held online June 9-11. The findings support the continued investigation of a higher dose treatment of…

You must be logged in to read/download the full post.